RxDoctor Payments Data

Ellen Wermter, NP

Family · Charlottesville, VANPI 1215452024

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Harmony Biosciences LLC at 50.7% of the total. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$251,164in general payments, 2019–2025

Across 560 payments — averaging $448.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$127K
  • Jazz Pharmaceuticals Inc.$60K
  • Axsome Therapeutics, Inc.$60K
  • Avadel CNS Pharmaceuticals, LLC$2K
  • Inspire Medical Systems, Inc.$1K
  • Novo Nordisk$25
  • plus $36 from 2 others

What the payments were for

  • Consulting fees$58,87723%
  • Speaking & faculty fees$129,96752%
  • Travel & lodging$51,97321%
  • Food & beverage$10,0644%
  • Education$2830%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$251,164 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$5,823
Medicare patients
41
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl48$562,673
XywavSodium,calcium,mag,pot Oxybate30$508,525
SunosiSolriamfetol Hcl12$12,023
Modafinil33$3,969
Ropinirole Hcl73$1,613
Gabapentin91$689
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$593
Armodafinil12$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$127,243$562,67348 claims
Axsome Therapeutics, Inc.Sunosi$59,952$12,02312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →